Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia

• DOI: 10.3389/fonc.2024.1340909
• Publication Date: 2024-04-24T07:55:56Z
• Authors: Sonia Ahmed; Mariam Elsherif; Dina Yassin; Nahla Elsharkawy; Ayman S. Mohamed; Nouran Yasser; Amr Elnashar; Hanafy Hafez; Edward A. Kolb; Alaa Elhaddad
• Keywords: Minimal Residual Disease

Molecular testing plays a pivotal role in monitoring measurable residual disease (MRD) acute myeloid leukemia (AML), aiding the refinement of risk stratification and treatment guidance. Wilms tumor gene 1 (